

**TRADEMARK ASSIGNMENT**

Electronic Version v1.1  
 Stylesheet Version v1.1

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	First Lien Intellectual Property Termination and Release

**CONVEYING PARTY DATA**

Name	Formerly	Execution Date	Entity Type
Bank of America, N.A., as Collateral Agent		07/03/2007	National Banking Association:

**RECEIVING PARTY DATA**

<b>Name:</b>	CIG Media Group, L.P.
<b>Street Address:</b>	3500 Maple Avenue
<b>Internal Address:</b>	Suite 750
<b>City:</b>	Dallas
<b>State/Country:</b>	TEXAS
<b>Postal Code:</b>	75219
<b>Entity Type:</b>	LIMITED PARTNERSHIP: DELAWARE

<b>Name:</b>	CURE Media Group, L.P.
<b>Street Address:</b>	3500 Maple Avenue
<b>Internal Address:</b>	Suite 750
<b>City:</b>	Dallas
<b>State/Country:</b>	TEXAS
<b>Postal Code:</b>	75219
<b>Entity Type:</b>	LIMITED PARTNERSHIP: DELAWARE

**PROPERTY NUMBERS Total: 5**

Property Type	Number	Word Mark
Registration Number:	2603244	CLINICAL COLORECTAL CANCER
Registration Number:	2603243	CLINICAL LYMPHOMA
Registration Number:	2574774	CLINICAL BREAST CANCER
Registration Number:	2574773	CLINICAL LUNG CANCER
Registration Number:	2800273	CURE CANCER UPDATES, RESEARCH & EDUCATION

CH \$140.00 2603244

CORRESPONDENCE DATA

Fax Number: (202)756-9299  
*Correspondence will be sent via US Mail when the fax attempt is unsuccessful.*  
Phone: 8002210770  
Email: matthew.mayer@thomson.com  
Correspondent Name: Corporation Service Company  
Address Line 1: 1133 Avenue of the Americas  
Address Line 2: Suite 3100  
Address Line 4: New York, NEW YORK 10036

ATTORNEY DOCKET NUMBER:	CSC # 982807
NAME OF SUBMITTER:	Matthew Mayer
Signature:	/Matthew Mayer/
Date:	07/05/2007

Total Attachments: 31  
source=BOA\_Cig\_TM5#page3.tif  
source=BOA\_Cig\_TM5#page4.tif  
source=BOA\_Cig\_TM5#page5.tif  
source=BOA\_Cig\_TM5#page6.tif  
source=BOA\_Cig\_TM5#page7.tif  
source=BOA\_Cig\_TM5#page8.tif  
source=BOA\_Cig\_TM5#page9.tif  
source=BOA\_Cig\_TM5#page10.tif  
source=BOA\_Cig\_TM5#page11.tif  
source=BOA\_Cig\_TM5#page12.tif  
source=BOA\_Cig\_TM5#page13.tif  
source=BOA\_Cig\_TM5#page14.tif  
source=BOA\_Cig\_TM5#page15.tif  
source=BOA\_Cig\_TM5#page16.tif  
source=BOA\_Cig\_TM5#page17.tif  
source=BOA\_Cig\_TM5#page18.tif  
source=BOA\_Cig\_TM5#page19.tif  
source=BOA\_Cig\_TM5#page20.tif  
source=BOA\_Cig\_TM5#page21.tif  
source=BOA\_Cig\_TM5#page22.tif  
source=BOA\_Cig\_TM5#page23.tif  
source=BOA\_Cig\_TM5#page24.tif  
source=BOA\_Cig\_TM5#page25.tif  
source=BOA\_Cig\_TM5#page26.tif  
source=BOA\_Cig\_TM5#page27.tif  
source=BOA\_Cig\_TM5#page28.tif  
source=BOA\_Cig\_TM5#page29.tif  
source=BOA\_Cig\_TM5#page30.tif  
source=BOA\_Cig\_TM5#page31.tif  
source=BOA\_Cig\_TM5#page32.tif  
source=BOA\_Cig\_TM5#page33.tif

Exhibit A

Trademarks

See attached.

**SCHEDULE I  
TO  
FIRST LIEN TRADEMARK SECURITY AGREEMENT**

<b>CIG Media Group, L.P.</b>		
<b>Owner</b>	<b>Registration Number</b>	<b>Trademark</b>
Cancer Information Group, L.P.	2603244	CLINICAL COLORECTAL CANCER
Cancer Information Group, L.P.	2603243	CLINICAL LYMPHOMA
Cancer Information Group, L.P.	2574774	CLINICAL BREAST CANCER
Cancer Information Group, L.P.	2574773	CLINICAL LUNG CANCER
Cancer Information Group, L.P.	unregistered	Clinical Prostate Cancer
Cancer Information Group, L.P.	unregistered	Supportive Cancer Therapy

<b>CURE Media Group, L.P.</b>		
<b>Owner</b>	<b>Registration Number</b>	<b>Trademark</b>
Cancer Information Group, L.P.	2800273	C.U.R.E. Cancer Updates, Research, and Education

## FIRST LIEN INTELLECTUAL PROPERTY TERMINATION AND RELEASE

THIS FIRST LIEN INTELLECTUAL PROPERTY TERMINATION AND RELEASE (this "Agreement") dated as of July 3, 2007, is made by and among PER Group, L.P. ("PER"), CIG Media Group, L.P. ("CIG") and CURE Media Group, L.P. ("CURE", and together with PER and CIG, the "Pledgors", each a "Pledgor") and Bank of America, N.A., collateral agent ("Agent") pursuant to that certain First Lien Credit Agreement, by and among MMH Partners, L.P., MMH Holdings, LLC and Medical Media Group, LLC, dated as of June 30, 2005 (as amended, the "First Lien Credit Agreement"). Capitalized terms used herein, but otherwise not defined, shall have the meanings ascribed to them in the First Lien Credit Agreement.

### RECITALS

A. CIG and CURE each granted a security interest in their respective trademarks identified on Exhibit A attached hereto (collectively, the "Trademarks") to Agent pursuant to that certain First Lien Trademark Security Agreement, dated June 30, 2005 (the "Trademark Security Agreement"), executed by Pledgors in favor of Agent.

B. Pledgors granted a security interest in their respective copyrights identified on Exhibit B attached hereto (collectively, the "Copyrights") to Agent, pursuant to that certain First Lien Copyright Security Agreement, dated June 30, 2005 (the "Copyright Security Agreement", and collectively with the Trademark Security Agreement, the "Security Agreements").

C. In order to evidence the grant of security interests under the Security Agreements, Pledgors caused the due execution and delivery of certain filings in the United States Patent and Trademark Office (the "USPTO") and the United States Copyright Office (the "USCO").

D. The Obligations under the First Lien Credit Agreement, the other Loan Documents and all documents and agreements delivered pursuant to the First Lien Credit Agreement or in connection therewith to the extent described therein have been terminated.

E. Agent has agreed to terminate and release all security interests granted to or held by Agent as security for the Obligations under the First Lien Credit Agreement and the other Loan Documents.

F. In order to evidence the release of the security interests granted pursuant to the Security Agreements, Pledgors have requested, and Agent has agreed, to execute and deliver this Agreement.

NOW THEREFORE, with intent to be legally bound hereby and for other good and valuable consideration, receipt of which is hereby acknowledged, Pledgors and Agent hereby agree as follows:

SECTION 1. Release and Discharge. Agent hereby terminates and releases all security interests granted to or held by it in the Trademarks and Copyrights pursuant to the Security Agreements as security for the Obligations under the First Lien Credit Agreement and the other

Loan Documents. Agent agrees that the Trademarks and Copyrights securing the Obligations are hereby released and discharged (without recourse, representation or warranty) from the security interests granted pursuant to the Security Agreements and such security interests are hereby reconveyed to Pledgors.

SECTION 2. Effectiveness. This Agreement becomes effective when all parties hereto have executed and delivered a counterpart hereof (including by way of facsimile transmission or other electronic transmission).

SECTION 3. Further Assurances. Agent agrees that it shall, from time to time, at the expense of Pledgors, execute, acknowledge and deliver to Pledgors and their respective designees, successors or assigns such instruments, agreements, and other documents as Pledgors or its successors or assigns shall reasonably request in order to further evidence the releases and discharges described in Section 1 above.

SECTION 4. Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of New York without giving effect to the conflict of laws principles thereof.


SECTION 5. Counterparts. This Agreement may be executed in any number of counterparts (including by facsimile or electronic transmission), each of which shall be an original, but all of which, taken together, shall constitute one and the same document.

[THE REMAINDER OF THIS PAGE IS INTENTIONALLY LEFT BLANK]


IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their respective officers thereunto duly authorized, as of the date first set forth above.

**PER GROUP, L.P.**  
**CIG MEDIA GROUP, L.P.**  
**CURE MEDIA GROUP, L.P.,**  
as Grantors

**By: MEDICAL MEDIA GROUP, LLC,**  
as sole general partner

By:   
Name: Kim Hall  
Title: Chief Financial Officer and  
Assistant Treasurer

**BANK OF AMERICA, N.A.,**  
as Collateral Agent for the First Lien Lenders

By:   
Name: Mark Kenneley  
Title: Managing Director

[SIGNATURE PAGE TO FIRST LIEN INTELLECTUAL PROPERTY TERMINATION AND RELEASE]



**Exhibit A**

**Trademarks**

See attached.

**SCHEDULE I  
TO  
FIRST LIEN TRADEMARK SECURITY AGREEMENT**

<b>CIG Media Group, L.P.</b>		
<b>Owner</b>	<b>Registration Number</b>	<b>Trademark</b>
Cancer Information Group, L.P.	2603244	CLINICAL COLORECTAL CANCER
Cancer Information Group, L.P.	2603243	CLINICAL LYMPHOMA
Cancer Information Group, L.P.	2574774	CLINICAL BREAST CANCER
Cancer Information Group, L.P.	2574773	CLINICAL LUNG CANCER
Cancer Information Group, L.P.	unregistered	Clinical Prostate Cancer
Cancer Information Group, L.P.	unregistered	Supportive Cancer Therapy

<b>CURE Media Group, L.P.</b>		
<b>Owner</b>	<b>Registration Number</b>	<b>Trademark</b>
Cancer Information Group, L.P.	2800273	C.U.R.E. Cancer Updates, Research, and Education

**Exhibit B**

**Copyrights**

See attached.

SCHEDULE I  
TO  
FIRST LIEN COPYRIGHT SECURITY AGREEMENT

<b>PER Group, L.P.</b>				
Publication Name	Vol.	No.	Date of Pub.	Copyright #
Acute Lymphoblastic Leukemia	2	2	Sep. 98	TX 5262833
Advances in Bladder Cancer	1	1	May 02	TX 5878265
Advances in Breast Cancer	1	1	Aug. 99	TX 4964007
	1	2	Sep. 99	TX 4992965
	1	3	Nov. 99	TX 5033727
	2	1	Jun. 00	TX 5235277
	2	2	Aug. 00	TX 5235277
	2	3	Dec. 00	TX 5295450
	3	1	Apr. 01	TX 5897147
	3	2	Jun. 01	TX 5897147
	3	3	Oct. 01	TX 5675428
	3	4	Dec. 01	TX 5675428
	4	1	Mar. 02	TX 5864063
	4	2	Apr. 02	TX 5675235
	4	3	Jul. 02	TX 5675235
	4	4	Sep. 02	TX 5840484
	5	1	Jan. 04	TX 5968193
	5	2	Aug. 04	TX 6110103
5	3	Sep. 04	TX 6110103	
Advances in Colon Cancer	2	2	Aug. 98	TX 4969392
	2	2	Sep. 98	TX 4969392
	2	3	Nov. 98	TX 4969393
	3	1	Sep. 99	TX 4992961
	4	1	Aug. 00	TX 5164590
	5	3	Nov. 01	TX 5864066
	6	1	Nov. 02	TX 5675502
	7	1	Jun. 03	TX 5839949
	7	2	Aug. 03	TX 5839949
	7	3	Sep. 03	TX 5983662
8	1	May 04	TX 6005724	
Advances in Gastrointestinal Malignancies	1	1	Apr. 02	TX 5721999
	1	2	Sep. 02	TX 5694868
Advances in Glioma Therapy	1	1	Apr. 00	TX 5164141
	1	2	Jun. 00	TX 5164141
	1	3	Sep. 00	TX 5255083

PER Group, L.P.				
Publication Name	Vol.	No.	Date of Pub.	Copyright #
Advances in Head & Neck Cancer	1	1	Oct. 02	TX 5694862
	2	1	Dec. 03	TX 5968184
Advances in Lung Cancer	2	1	Feb. 00	TX 5158550
	2	2	Mar. 00	TX 5158550
	2	3	Apr. 00	TX 5158550
	2	4	Aug. 00	TX 5164589
	2	5	Nov. 00	TX 5290303
	4	1	Sep. 02	TX 5694865
	4	2	Nov. 02	TX 5657892
	4	3	Nov. 02	TX 5657892
	5	1	May 03	TX 5881290
	5	2	Sep. 03	TX 5881291
	5	3	Oct. 03	TX 5940807
	5	4	Dec. 03	TX 5940807
	5	5	Dec. 03	TX 5940807
	6	1	Jun. 04	TX 6151113
	6	2	Sep. 04	TX 6110106
	Advances in Ovarian Cancer	1	1	Dec. 01
1		2	Apr. 02	TX 5595750
1		3	Dec. 02	TX 5675504
2		1	May 03	TX 5881288
2		2	Dec. 03	TX 5983663
Advances in Prostate Cancer	1	3	Feb. 97	TX 4987315
	1	4	Jul. 97	TX 4987321
	2	2	Aug. 98	TX 4987322
	3	1	Feb. 99	TX 4987320
	3	2	Dec. 99	TX 5180472
	4	1	Mar. 00	TX 5164253
	4	2	Jun. 00	TX 5164253
	6	1	Jan. 02	TX 5606945
	6	2	Mar. 02	TX 5606945
	6	3	Apr. 02	TX 5606945
	6	4	Dec. 02	TX 5675508
Anemia in Oncology/ Anemia in Quality of Life in Oncology			Mar. 98	TX 4969394
	1	1	Jul. 98	TX 4969396
	1	3	Oct. 98	TX 5172641
	1	5	Dec. 98	TX 5172642
	2	1	Mar. 98	TX 4969394
	2	1	Jul. 98	TX 4969396

PER Group, L.P.				
Publication Name	Vol.	No.	Date of Pub.	Copyright #
	2	1	Mar. 99	TX 4969395
	2	2	May 99	TX 4994943
	2	3	Sep. 99	TX 4995252
	2	4	Dec. 99	TX 5662146
	2	4	Dec. 99	TX 5239597
	3	1	Feb. 00	TX 5287413
	3	2	Mar. 00	TX 5164138
	3	3	May 00	TX 5164138
	3	4	July 00	TX 5282021
	3	4	Jul. 00	TX 5231587
	3	5	Aug. 00	TX 5164588
	3	6	Dec. 00	TX 5254878
	4	3	Aug. 01	TX 5601685
	4	4	Sep. 01	TX 5601685
	5	1	Jan. 02	TX 5601679
	5	2	Mar. 02	TX 5601679
	5	3	Mar. 02	TX 5601679
	5	4	Oct. 02	TX 5657887
	5	5	Dec. 02	TX 5657887
Arixtra Monograph	1	1	Jan. 03	TX 5722528
Avastin Monograph	1	1	Apr. 04	TX 6094634
	1	2	Jul. 04	TX 6154302
Biological Therapy of Breast Cancer	2	1	Jan. 00	TX 5170579
	2	2	Aug. 00	TX 5164586
	2	4	Jun. 01	TX 5623118
	2	5	Sep. 01	TX 5623118
	2	6	Oct. 01	TX 5600109
	3	1	Nov. 01	TX 5600109
	4	1	Mar. 02	TX 5600108
	4	2	Jun. 02	TX 5600108
	4	3	Sep. 02	TX 5657883
	4	4	Dec. 02	TX 5657883
	5	1	Jun. 04	TX 6151111
	5	2	Sep. 04	TX 6145398
	5	3	Dec. 04	TX 6145398
Biological Therapy of Cancer	1	1	Mar. 03	TX 5719785
	1	2	Jun. 03	TX 5839970
	1	3	Jul. 03	TX 5839970
	1	4	Sep. 03	TX 5839970
	2	1	Apr. 04	TX 6092653
	2	2	May 04	TX 6092653

PER Group, L.P.				
Publication Name	Vol.	No.	Date of Pub.	Copyright #
Biological Therapy of Genitourinary Tumors	1	1	Jun. 99	TX 4978646
	1	2	Aug. 99	TX 4994942
Biological Therapy of Leukemia	1	1	May 00	TX 5231588
	1	2	Jul. 00	TX 5295448
	1	3	Sep. 00	TX 5264697
	1	4	Dec. 00	TX 5262140
	2	1	Oct. 01	TX 5970960
Biological Therapy of Lymphoma	1	1	Apr. 98	TX 4941080
	1	2	May 98	TX 4941081
	1	3	Summer 98	TX 4941082
	1	4	Oct. 98	TX 4955982
	1	5	Dec. 98	TX 4941077
	2	1	Mar. 99	TX 4941078
	2	2	May 99	TX 4994940
	2	3	Jul. 99	TX 4963861
	3	1	Jan. 00	TX 5170578
	3	2	Apr. 00	TX 5158549
	3	3	Jun. 00	TX 5158549
	3	4	Sep. 00	TX 5295397
	4	1	Feb. 01	TX 5683154
	4	2	Apr. 01	TX 5683154
	4	3	Jul. 01	TX 5864074
	4	4	Nov. 01	TX 5864069
	5	3	Sep. 02	TX 5683171
	5	4	Oct. 02	TX 5683171
	5	5	Nov. 02	TX 5694939
	6	1	Apr. 03	TX 5839918
	6	2	May 03	TX 5839918
6	3	Oct. 03	TX 5943514	
6	4	Nov. 03	TX 5943514	
7	1	May 04	TX 6083497	
7	2	Jun. 04	TX 6083497	
7	3	Dec. 04	TX 6151112	
Bone Metastases in Cancer	1	1	Winter 98	TX 4995601
Breast Cancer Journal Club	2	1	May 02	TX 5682952
	2	2	Jul. 02	TX 5682952
	2	3	Nov. 02	TX 5693317
	3	1	Jan. 03	TX 5707346
	3	2	Apr. 03	TX 5983783
	4	1	Jan. 04	TX 5968179

PER Group, L.P.				
Publication Name	Vol.	No.	Date of Pub.	Copyright #
	4	2	May 04	TX 6006368
Cancer Abstracts & Summaries	1	1	Sep. 00	TX 5242375
	1	2	Dec. 00	TX 5242375
	2	1	Feb. 01	TX 5864070
	2	2	Jun. 01	TX 5675430
	2	3	Jul. 01	TX 5675430
	2	4	Aug. 01	TX 5675430
	2	5	Aug. 01	TX 5675429
	2	6	Oct. 01	TX 5675429
	3	1	Feb. 02	TX 5892417
	3	2	Mar. 02	TX 5892417
	3	3	May 02	TX 5892417
	3	4	May 02	TX 5892417
	3	5	Aug. 02	TX 5675431
	3	6	Aug. 02	TX 5675431
	3	7	Aug. 02	TX 5675431
	3	8	Aug. 02	TX 5675431
	3	9	Aug. 02	TX 5675431
	3	10	Aug. 02	TX 5683172
	3	10	Aug. 02	TX 5675431
	3	11	Aug. 02	TX 5675431
	3	12	Sep. 02	TX 5683172
	3	13	Oct. 02	TX 5683172
	3	14	Oct. 02	TX 5657891
	3	15	Dec. 02	TX 5657891
	3	16	Dec. 02	TX 5657891
	4	1	Mar. 03	TX 5693794
	4	2	Mar. 03	TX 5693794
	4	3	Apr. 03	TX 5839916
	4	4	Apr. 03	TX 5839916
	4	5	Mar. 03	TX 5839916
	4	6	Mar. 03	TX 5839916
	4	7	Apr. 03	TX 5839916
	4	8	Mar. 03	TX 5839916
	4	9	Apr. 03	TX 5839916
	4	10	Aug. 03	TX 5839888
	4	11	Jul. 03	TX 5839888
	4	12	Jul. 03	TX 5839888
	4	13	Jul. 03	TX 5839888
	4	14	Aug. 03	TX 5839888
	4	15	Oct. 03	TX 5940251
	4	16	Oct. 03	TX 5940251
	4	17	Sep. 03	TX 5839888
	4	18	Nov. 03	TX 5940251
	4	19	Oct. 03	TX 5940251



PER Group, L.P.				
Publication Name	Vol.	No.	Date of Pub.	Copyright #
	4	20	Oct. 03	TX 5940251
	4	21	Oct. 03	TX 5940251
	4	22	Dec. 03	TX 5940251
	4	23	Dec. 03	TX 5940251
	5	1	Apr. 04	TX 6005723
	5	2	Feb. 04	TX 5940256
	5	3	Feb. 04	TX 5940256
	5	4	Mar. 04	TX 5940256
Cancer Conference Highlights	1	2	Jan. 97	TX 4978637
	2	3	Apr. 98	TX 4978647
	2	4	Jul. 98	TX 4978633
	2	5	Jul. 98	TX 4978634
	2	6	Jul. 98	TX 4978632
	2	7	Sep. 98	TX 4978636
	2	8	Oct. 98	TX 5028724
	2	9	Oct. 98	TX 4978635
	2	10	Nov. 98	TX 4978649
	2	11	Nov. 98	TX 4978648
	3	1	Jan. 99	TX 4978641
	3	2	Mar. 99	TX 4978640
	3	3	Apr. 99	TX 4978639
	3	3	Apr. 99	TX 5033726
	3	4	Apr. 99	TX 4978643
	3	5	Apr. 99	TX 4978638
	3	6	Apr. 99	TX 4978642
	3	7	Apr. 99	TX 4978644
	3	8	Jun. 99	TX 4992787
	3	9	Aug. 99	TX 4995258
	3	10	Aug. 99	TX 5662145
	3	10	Aug. 99	TX 5058120
	3	11	Oct. 99	TX 5662144
	3	12	Dec. 99	TX 5662147
	3	13	Oct. 99	TX 5662148
	3	14	Oct. 99	TX 5033728
	3	15	Nov. 99	TX 5033729
	4	1	Jan. 00	TX 5294180
	4	2	Mar. 00	TX 5172643
	4	4	Jun. 00	TX 5184363
	4	5	Jul. 00	TX 5184363
	4	6	Jul. 00	TX 5184363
	4	7	Aug. 00	TX 5184363
	4	8	Sep. 00	TX 5184363
	4	9	Sep. 00	TX 5239739
	4	10	Oct. 00	TX 5239739
	4	11	Oct. 00	TX 5239739

PER Group, L.P.				
Publication Name	Vol.	No.	Date of Pub.	Copyright #
	4	12	Oct. 00	TX 5239739
	4	13	Oct. 00	TX 5239739
	4	14	Dec. 00	TX 5239739
	5	6	Oct. 01	TX 5606946
	5	7	Nov. 01	TX 5606946
	5	8	Dec. 01	TX 5606946
	6	7	Jun. 02	TX 5682954
	6	8	Jun. 02	TX 5682954
	6	9	Jul. 02	TX 5682954
	6	10	Oct. 02	TX 5657890
	6	11	Oct. 02	TX 5657890
	6	12	Oct. 02	TX 5657890
	6	13	Dec. 02	TX 5657890
	6	14	Dec. 02	TX 5657890
	7	1	Feb. 03	TX 5693793
	7	2	Feb. 03	TX 5693793
	7	3	Mar. 03	TX 5693793
	7	4	Mar. 03	TX 5693793
	7	5	Mar. 03	TX 5842077
	7	6	Apr. 03	TX 5842077
	7	8	Jul. 03	TX 5839950
	7	9	Jul. 03	TX 5839950
	7	10	Jul. 03	TX 5839950
	7	10	Jul. 03	TX 5839950
	7	11	Jul. 03	TX 5839950
	7	12	Oct. 03	TX 5940808
	7	13	Sep. 03	TX 5839950
	7	14	Sep. 03	TX 5839950
	7	15	Sep. 03	TX 5839950
	7	16	Sep. 03	TX 5839950
	7	17	Oct. 03	TX 5940808
<b>Capecitabine Clinical Update</b>	1	1	Mar. 02	TX 5609196
	1	2	May 02	TX 5609196
	2	1	Mar. 03	TX 5722086
	2	3	Sep. 03	TX 5983661
<b>Case Studies in Breast Cancer</b>	1	1	Feb. 02	TX 5897144
	1	2	Apr. 02	TX 5897144
	1	3	Apr. 02	TX 5897145
	1	4	Jun. 02	TX 5897145
	1	5	Sep. 02	TX 5683156
	1	6	Oct. 02	TX 5683156
	1	7	Nov. 02	TX 5657888
	1	8	Nov. 02	TX 5657888
	1	9	Dec. 02	TX 5657888

PER Group, L.P.				
Publication Name	Vol.	No.	Date of Pub.	Copyright #
	1	10	Dec. 02	TX 5657888
	2	1	Jan. 03	TX 5722084
	2	2	Oct. 03	TX 5940253
	2	3	May 03	TX 5901389
	2	4	Sep. 03	TX 5940253
	3	1	Apr. 04	TX 5940255
	3	2	Apr. 04	TX 5940255
Case Studies in Colorectal Cancer	1	1	Jan. 02	TX 5682953
	1	2	Feb. 02	TX 5682953
	1	3	Mar. 02	TX 5682953
	1	4	Apr. 02	TX 5682953
	1	5	Oct. 02	TX 5683169
	1	6	Oct. 02	TX 5683169
	1	7	Nov. 02	TX 5657885
	1	8	Nov. 02	TX 5657885
	2	1	Apr. 03	TX 5839920
	2	2	Apr. 03	TX 5839920
	2	3	Jun. 03	TX 5839920
	2	4	Jul. 03	TX 5839920
	2	5	Aug. 03	TX 5839920
	3	1	Apr. 04	TX 6005722
	3	2	Jul. 04	TX 6151114
	3	3	Oct. 04	TX 6145399
	3	4	Dec. 04	TX 6145399
Case Studies in Leukemia	1	2	Jun. 02	TX 5878272
	1	3	Sep. 02	TX 5694869
	1	4	Dec. 02	TX 5657882
	1	5	Dec. 02	TX 5657882
	2	1	Jun. 03	TX 5855057
Case Studies in Lung Cancer	1	1	Jan. 02	TX 5609195
	1	2	Feb. 02	TX 5609195
	1	3	Feb. 02	TX 5609195
	1	4	Jun. 02	TX 5601680
	1	5	Jul. 02	TX 5601680
	1	6	Jul. 02	TX 5601680
	1	7	Aug. 02	TX 5601680
	1	8	Nov. 02	TX 5657889
	1	9	Dec. 02	TX 5657889
	1	11	Dec. 02	TX 5657889
	2	1	Jan. 03	TX 5675506
	2	2	May 03	TX 5839917
	2	3	Apr. 03	TX 5839917
	2	3	Apr. 03	TX 5839917

PER Group, L.P.				
Publication Name	Vol.	No.	Date of Pub.	Copyright #
	2	4	Apr. 03	TX 5839917
	2	5	Sep. 03	TX 5835734
	3	1	Mar. 04	TX 5940809
	3	2	Mar. 04	TX 5940809
	3	3	Mar. 04	TX 5940809
	3	4	Apr. 04	TX 5940809
	3	7	Dec. 04	TX 6151117
<b>Case Studies in Lymphoma</b>	1	1	Apr. 02	TX 5675432
	1	2	Jul. 02	TX 5675432
	1	3	Aug. 02	TX 5683155
	1	4	Oct. 02	TX 5683155
	1	5	Nov. 02	TX 5675510
	2	1	Mar. 03	TX 5839887
	2	2	Apr. 03	TX 5839887
	2	3	Aug. 03	TX 5839886
	2	4	Apr. 03	TX 5839887
	2	5	May 03	TX 5839887
	2	6	Aug. 03	TX 5839886
	2	7	Nov. 03	TX 5940250
	2	8	Nov. 03	TX 5940250
	3	1	Jul. 04	TX 6151093
<b>Case Studies in Medicine</b>	1	1	Apr. 04	TX 6102773
<b>Case Studies in Oncology</b>	1	1	Dec. 99	TX 5066600
	2	1	Feb. 00	TX 5164139
	2	2	Apr. 00	TX 5164139
	2	3	Apr. 00	TX 5164139
	2	4	May 00	TX 5164134
	2	5	Jun. 00	TX 5164134
	2	6	Aug. 00	TX 5308464
	2	7	Oct. 00	TX 5290305
	2	8	Nov. 00	TX 5290306
	2	9	Nov. 00	TX 5242366
	2	10	Nov. 00	TX 5242366
	2	11	Nov. 00	TX 5242366
	2	12	Nov. 00	TX 5242366
	2	13	Dec. 00	TX 5242366
	3	1	Feb. 01	TX 5682956
	3	2	Feb. 01	TX 5682956
	3	3	Feb. 01	TX 5682956
	3	4	Mar. 01	TX 5682956
	3	5	Mar. 01	TX 5682956
	3	6	Mar. 01	TX 5682956
	3	7	Apr. 01	TX 5682956

PER Group, L.P.				
Publication Name	Vol.	No.	Date of Pub.	Copyright #
	3	8	May 01	TX 5683167
	3	9	Jun. 01	TX 5683167
	3	10	Jun. 01	TX 5683167
	3	11	Jun. 01	TX 5683167
	3	12	Jul. 01	TX 5683167
	3	13	Jul. 01	TX 5683167
	3	14	Aug. 01	TX 5682958
	3	15	Sep. 01	TX 5682958
	3	16	Sep. 01	TX 5682958
	3	17	Sep. 01	TX 5682958
	3	18	Oct. 01	TX 5682958
	3	19	Oct. 01	TX 5682958
	3	20	Oct. 01	TX 5682958
	3	21	Nov. 01	TX 5683168
	3	22	Nov. 01	TX 5683168
	3	23	Nov. 01	TX 5683168
	3	24	Dec. 01	TX 5683168
	3	25	Dec. 01	TX 5683168
	4	1	Jul. 02	TX 5897151
	4	2	Jul. 02	TX 5897151
	4	3	Aug. 02	TX 5897151
	4	4	Nov. 02	TX 5657884
	4	5	Nov. 02	TX 5657884
	4	6	Dec. 02	TX 5657884
	4	7	Dec. 02	TX 5657884
	5	1	Apr. 03	TX 5839885
	5	2	Apr. 03	TX 5839885
	5	3	Oct. 03	TX 5940806
	5	4	Aug. 03	TX 5842079
	5	6	Sep. 03	TX 5842079
	5	7	Nov. 03	TX 5940806
	5	8	Nov. 03	TX 5940806
	5	9	Dec. 03	TX 5940806
	5	10	Dec. 03	TX 5940806
	6	1	Feb. 04	TX 5940805
	6	2	Feb. 04	TX 5940805
	6	3	Apr. 04	TX 6092776
	6	4	Jul. 04	TX 6151110
		Compilation	May 04	TX 6092776
<b>Case Studies in Ovarian Cancer</b>	1	1	May 02	TX 5864071
	1	2	Sep. 02	TX 5694867
	1	2	Oct. 02	TX 5694867
	1	3	Dec. 02	TX 5675503
	2	1	Oct. 03	TX 5940252
	2	2	Nov. 03	TX 5940252

PER Group, L.P.				
Publication Name	Vol.	No.	Date of Pub.	Copyright #
	2	3	Sep. 04	TX 6151107
Case Studies in Prostate Cancer	1	1	Mar. 02	TX 5864072
	1	2	Jul. 02	TX 5864073
	1	3	Nov. 02	TX 5675513
Case Studies in Supportive Care	1	1	Dec. 02	TX 5675226
	1	2	Dec. 02	TX 5675226
	2	1	Jul. 03	TX 5835735
	3	1	Mar. 04	TX 5968187
Chiron CD Project	1	1	Oct. 03	TX 5972426
Chronic myelogenous leukemia: the cutting edge	1	1	Apr. 99	TX 4995602
CLL: The Cutting Edge	1	2	Dec. 96	TX 5192622
	2	1	Summer 97	TX 5192623
	3	1	Winter 98	TX 4987319
	3	2	Summer 98	TX 4995597
	3	3	Sep. 98	TX 4995600
	3	4	Oct. 98	TX 4995595
	3	5	Dec. 98	TX 4995598
	4	1	Mar. 99	TX 4995593
	4	2	Jun. 99	TX 4986093
	5	1	Feb. 00	TX 5247415
	5	1	Feb. 00	TX 5233972
	5	2	May 00	TX 5233972
	5	3	Jul. 00	TX 5601682
	5	4	Sep. 00	TX 5601682
	5	4	Sep. 00	TX 5261632
	5	5	Dec. 00	TX 5595749
	5	5	Dec. 00	TX 5261632
	6	1	Feb. 01	TX 5897146
	6	2	May 01	TX 5897146
	6	3	Aug. 01	TX 5897150
	6	4	Nov. 01	TX 5897150
	7	1	Mar. 02	TX 5601681
	7	2	Apr. 02	TX 5601681
	7	3	May 02	TX 5601681
	7	4	Dec. 02	TX 5675511
	8	1	May 03	TX 5839919
	8	2	Aug. 03	TX 5839919
	9	1	Jan. 04	TX 5968182
	9	3	Jun. 04	TX 5968185
	9	5	Oct. 04	TX 6151109

PER Group, L.P.				
Publication Name	Vol.	No.	Date of Pub.	Copyright #
CML: The Cutting Edge	1	1	Apr. 99	TX 4995602
Clinical Experience w/Arsenic Trioxide			May 04	TX 6009332
Clinical Implications of Anemia in Oncology	1	1	Apr. 03	TX 5839969
	1	2	May 03	TX 5839969
	1	3	Nov. 03	TX 5968189
	2	1	May 04	TX 6011666
Current Advances in Emesis Control	1	1	Sep. 98	TX 4987317
	1	2	Oct. 98	TX 5004538
	1	3	Dec. 98	TX 4987316
			Oct. 99	TX 5004538
	2	1	Sep. 02	TX 5694866
	2	2	Nov. 02	TX 5675512
	3	1	Nov. 03	TX 5968192
Current Trends in Anthracyclines	1	1	Aug. 02	TX 5728666
	2	1	Oct. 04	TX 6151116
	2	2	Nov. 04	
Docetaxel in HRPC/ Docetaxel in hormone-refractory prostate cancer			Oct. 00	TX 5354605
Human Epidermal Growth Factor Receptors in Oncology (HEGFR)	1	2	Feb. 04	TX 5940800
	1	3	Mar. 04	TX 5940800
HER2 in Oncology	1	1	Apr. 00	TX 5164136
	1	2	May 00	TX 5164136
	1	3	Dec. 00	TX 5295396
	1	4	Apr. 01	TX 5864065
	1	5	Sep. 01	TX 5601684
	2	1	Oct. 01	TX 5601684
	2	2	Dec. 01	TX 5601684
	3	1	Feb. 02	TX 5927840
	3	2	Apr. 02	TX 5927840
	3	3	Oct. 02	TX 5694864
	3	4	Dec. 02	TX 5675509
	4	1	Apr. 03	TX 5968188
	Hormonal Therapy: A 2004 Perspective	1	1	May 04
Immune-Enhancing Cytokines	1	1		TX 504721
			Aug. 99	TX 5287418

PER Group, L.P.				
Publication Name	Vol.	No.	Date of Pub.	Copyright #
			Aug. 99	TX 5047221
	2	1	Feb. 00	TX 5262842
	2	2	Nov. 00	TX 5624993
	3	2	Aug. 01	TX 5864064
	4	1	May 02	TX 5596488
	4	2	Jul. 02	TX 5596488
	4	3	Nov. 02	TX 5675501
	5	1	Aug. 03	TX 5839948
	5	2	Sep. 03	TX 5839948
	6	1	May 04	TX 6094667
Immunomodulation in Transplantation	1	1	Jul. 98	TX 4995599
Infections in Oncology	1	1	Jun. 97	TX 5062165
	1	2	Oct. 97	TX 4995256
	1	3	Nov. 97	TX 4955981
	2	1	Mar. 98	TX 4941079
	2	2	Aug. 98	TX 4941076
	2	3	Sep. 98	TX 4941075
	2	4	Oct. 98	TX 4941072
	2	5	Dec. 98	TX 4941071
	3	1	May 99	TX 5662142
	3	1	May 99	TX 5058119
	3	2	Jul. 99	TX 4963860
	3	3	Sep. 99	TX 4992963
	4	1	Jan. 00	TX 5287414
	4	2	May 00	TX 5164135
	4	3	Jul. 00	TX 5164135
	4	4	Nov. 00	TX 5331659
	5	1	Apr. 01	TX 5682957
	5	2	Jun. 01	TX 5682957
	5	3	Oct. 01	TX 5864062
Lung Cancer Journal Club	1	1	Feb. 01	TX 5841462
	3	1	Jun. 03	TX 5878528
	4	1	Mar. 04	TX 5968178
Lymphoma Biology & Research	2	2	Spring 97	TX 5033730
	4	2	Oct. 98	TX 5243186
	5	1	Oct. 99	TX 5033731
	6	1	Dec. 00	TX 5294181
	7	1	May 02	TX 5864068
Lymphoma Journal Club	1	1	Feb. 00	TX 5164558
	1	2	Jun. 00	TX 5255322



PER Group, L.P.				
Publication Name	Vol.	No.	Date of Pub.	Copyright #
	1	2	Jun. 00	TX 5247404
	1	3	Oct. 00	TX 5295202
	1	4	Dec. 00	TX 5262263
	2	1	Apr. 01	TX 5897143
	2	2	Jun. 01	TX 5897143
	2	3	Oct. 01	TX 5897142
	2	4	Dec. 01	TX 5897142
	3	1	Mar. 02	TX 5897139
	3	2	May 02	TX 5897139
	3	3	Oct. 02	TX 5675227
	3	4	Nov. 02	TX 5675227
	4	1	Jun. 03	TX 5878526
	4	2	Nov. 03	TX 5968176
Monographs in Breast Cancer	1	1	Feb. 03	TX 5719787
	2	1	May 04	TX 6011667
Monographs in Gastrointestinal Cancer	1	1	Nov. 03	TX 5968222
	1	2	Jan. 04	TX 5940249
	1	1 & 2	Mar. 04	TX 5940249
Monographs in Lung Cancer	1	1	Nov. 03	TX 5968190
Monographs in Lymphoma	1	1	Oct. 99	TX 5047130
	2	1	Jun. 01	TX 5623117
	2	2	Sep. 01	TX 5623117
	3	1	Feb. 02	TX 5600107
	3	2	May 02	TX 5600107
	3	3	Aug. 02	TX 5694863
	4	1	Jul. 03	TX 5842078
	4	2	Sep. 03	TX 5842078
	5	1	Jul. 04	TX 6145397
	5	2	Sep. 04	TX 6145397
Neutropenia in Oncology	1	1	Dec. 01	TX 5626027
	1	2	Dec. 01	TX 5626027
	2	1	Feb. 02	TX 5819626
	2	2	May 02	TX 5600110
	2	3	Jun. 02	TX 5600110
	2	4	Oct. 02	TX 5694870
New Developments in Lung Cancer	1	1	Oct. 02	TX 5683170
	1	2	Oct. 02	TX 5683170
Oncology Abstracts	1	1	Oct. 03	TX 5968191

PER Group, L.P.				
Publication Name	Vol.	No.	Date of Pub.	Copyright #
	2	1	Oct. 04	TX 6151108
<b>Oncology Briefings</b>	1	1	Mar. 03	TX 5719786
	1	2	Jul. 03	TX 5842076
	1	3	Jul. 03	TX 5842076
	1	4	Jul. 03	TX 5842076
	1	5	Aug. 03	TX 5842076
	1	6	Nov. 03	TX 5940254
	1	7	Sep. 03	TX 5842076
	1	8	Sep. 03	TX 5968186
	1	9	Dec. 03	TX 5940254
	2	1	Jan. 04	TX 5955166
	2	2	Jan. 04	TX 5955166
	2	3	Jan. 04	TX 5955166
	2	4	Jan. 04	TX 5955166
	2	5	Feb. 04	TX 5955166
	2	6	Feb. 04	TX 5955166
	2	7	Feb. 04	TX 5955166
	2	8	Mar. 04	TX 5955166
	2	9	Apr. 04	TX 5955166
	2	10	Jun. 04	TX 6011665
	2	14	Aug. 04	TX 6112440
	2	15	Dec. 04	TX 6112439
	3	1	Jan. 05	TX 6112439
<b>Oncology Journal Club</b>	1	1	Mar. 03	TX 5868903
	1	1	Mar. 03	TX 5842080
	1	2	Jun. 03	TX 5842080
	1	3	Oct. 03	TX 5968177
<b>Oxaliplatin Investigator Newsletter</b>	1	1	May 03	TX 5881289
	1	2	Dec. 03	TX 5968180
<b>Phase III Chemo Trials in NSCLC</b>	1	1	May 99	TX 4978645
<b>Purine Analogues</b>	1	1	Jun. 05	TX 4995594
	2	1	Jun. 99	TX 4994939
	2	2	Nov. 99	TX 5662143
<b>Rituximab Investigator Newsletter</b>	1	1	Aug. 99	TX 4992962
	2	4	Dec. 00	TX 5262141
	3	3	Oct. 01	TX 5878264
	4	1	Jun. 02	TX 5601678
	4	2	Aug. 02	TX 5601678

Schedule 1 - Page 15

DAI:W1147401\BTR\011.DOC\68500.0008

TRADEMARK  
REEL: 003574 FRAME: 0969

PER Group, L.P.				
Publication Name	Vol.	No.	Date of Pub.	Copyright #
	4	3	Oct. 02	TX 5657886
	4	4	Dec. 02	TX 5657886
	5	1	Mar. 03	TX 5722089
	5	2	Jun. 03	TX 5901390
	5	3	Oct. 03	TX 5968181
	6	1	Feb. 04	TX 5968183
<b>Supportive Care in Oncology</b>	1	1	Dec. 02	TX 5675505
<b>Targeted Therapies in Oncology</b>	1	1	Nov. 01	TX 5864067
	2	1	Jan. 02	TX 5601683
	2	2	Apr. 02	TX 5601683
	2	3	Dec. 02	TX 5675500
	3	1	Jan. 03	TX 5722085
	4	1	Nov. 04	TX 6151115
<b>Therapeutic Isotopes in Cancer</b>	1	1	Sep. 99	TX 5047220
	1	2	Nov. 99	TX 5062166
	2	1	Mar. 00	TX 5247414
	2	1	Mar. 00	TX 5295449
<b>Thrombosis in Oncology</b>	1	1	Jun. 98	TX 4995257
	1	2	Nov. 98	TX 4941074
	2	1	Mar. 00	TX 5295449
	2	1	Mar. 99	TX 4941073
	2	2	May 99	TX 4994941
	2	3	Jul. 99	TX 4995255
	2	4	Sep. 99	TX 4992964
	3	1	Apr. 00	TX 5164137
	3	2	Jun. 00	TX 5164137
	3	3	Jul. 00	TX 5164137
	3	4	Sep. 00	TX 5242360
	3	5	Oct. 00	TX 5242360
	3	6	Dec. 00	TX 5242360
	4	1	Mar. 01	TX 5897148
	4	2	Apr. 01	TX 5897148
	4	3	Jul. 01	TX 5606947
	4	4	Sep. 01	TX 5606947
	5	1	Apr. 02	TX 5983080
	5	2	Sep. 02	TX 5683166
	5	3	Oct. 02	TX 5683166
5	4	Dec. 02	TX 5675507	
<b>Venous thromboembolism prevention: what nurses need to know to manage successful outcomes</b>			Jan. 03	TX 5722528

PER Group, L.P.				
Publication Name	Vol.	No.	Date of Pub.	Copyright #

**CIG Media Group, L.P.**

Publication Name	Vol.	No.	Date of Pub.	Copyright #
Clinical Breast Cancer	1	1	Apr. 00	TX 5-320-640
	1	2	Jul. 00	TX 5-354-587
	1	3	Oct. 00	TX 5-321-509
	1	4	Jan. 01	TX 5-353-219
	1	S1	Sep. 00	TX 5-321-509
	2	1	Apr. 01	TX 5-322-418
	2	2	Jul. 01	TX 5-429-532
	2	S1	Oct. 01	TX 5-525-811
	2	2	Oct. 01	TX 5-525-811
	2	4	Jan. 02	TX 5-626-487
	3	1	Apr. 02	TX 5-602-009
	3	2	Jun. 02	TX 5-602-009
	3	3	Aug. 02	TX 5-693-671
	3	4	Oct. 02	TX 5-693-671
	3	5	Dec. 02	TX 5-867-638
	3	S3	Dec. 02	TX 5-867-638
	3	S4	Feb. 03	TX 5-868-040
	3	6	Feb. 03	TX 5-868-040
	4	1	Apr. 03	TX 5-803-872
	4	S1	Apr. 03	TX 5-803-872
	4	2	Jun. 03	TX 5-803-872
	4	3	Aug. 03	TX 5-868-837
	4	4	Oct. 03	TX 5-868-837
	4	S2	Nov. 03	TX 6-116-225
	4	S3	Jan. 04	TX 6-116-256
	5	1	Apr. 04	TX 6-093-226
	5	2	Jun. 04	TX 6-093-226
	5	3	Aug. 04	TX 6-093-225
	5	4	Oct. 04	TX 6-093-225
	5	5	Dec. 04	TX 6-116-353
5	S1	Sep. 04	TX 6-116-257	
5	6	Feb. 05	TX 6-148-757	
Clinical Colorectal Cancer	1	1	May 01	TX 5-399-017
	1	2	Aug. 01	TX 5-428-976
	1	3	Nov. 01	TX 5-535-611
	1	4	Feb. 02	TX 5-582-352
	2	1	May 02	TX 6-035-553
	2	2	Aug. 02	TX 5-708-686
	2	3	Nov. 02	TX 5-470-492
	2	4	Feb. 03	TX 5-868-474
	3	1	May 03	TX 5-841-222

CIG Media Group, L.P.				
Publication Name	Vol.	No.	Date of Pub.	Copyright #
	3	2	Aug. 03	TX 5-907-387
	3	3	Nov. 03	TX 6-025-552
	3	4	Feb. 04	TX 5-972-254
	4	1	Apr. 04	TX 6-116-352
	4	S1	Jun. 04	TX 6-116-349
	4	2	Jul. 04	TX 6-116-350
	4	3	Sep. 04	TX 6-116-354
	4	S2	Oct. 04	TX 6-116-355
	4	4	Nov. 04	TX 6-116-348
	4	5	Jan. 05	TX 6-116-358
Clinical Lung Cancer	1	1	Aug. 99	TX 5-311-176
	1	2	Nov. 99	TX 5-344-097
	1	3	Feb. 00	TX 5-322-393
	1	4	May 00	TX 5-315-306
	1	S1	Apr. 00	TX 5-315-306
	2	1	Aug. 00	TX 5-311-178
	2	2	Nov. 00	TX 5-318-743
	2	3	Feb. 01	TX 5-353-216
	2	4	May 01	TX 5-345-352
	2	S1	Dec. 00	TX 5-318-743
	2	S2	May 01	TX 5-345-352
	3	1	Aug. 01	TX 5-335-483
	3	2	Nov. 01	TX 5-519-326
	3	3	Feb. 02	TX 5-581-652
	3	S1	Mar. 02	TX 5-581-652
	3	4	May 02	TX 5-682-955
	4	1	Jul. 02	TX 5-682-955
	4	2	Sep. 02	TX 5-693-404
	4	3	Nov. 02	TX 5-693-404
	4	S1	Nov. 02	TX 5-693-404
	4	4	Jan. 03	TX 5-868-225
	4	5	Mar. 03	TX 5-868-225
	4	6	May 03	TX 5-868-256
	5	1	Jul. 03	TX 5-868-256
	5	1	Sep. 03	TX 5-874-667
	5	S1	Sep. 03	TX 5-874-667
	5	2	Nov. 03	5-874-667
	5	S2	Nov. 03	TX 5-874-667
	5	3	Nov. 03	TX 5-874-667
	5	4	Jan. 04	TX 6-092-654
	5	5	Mar. 04	TX 6-092-654
	5	S2	Apr. 04	TX 6-092-654
	5	6	May 04	TX 6-116-359
	6	1	Jul. 04	TX 6-116-357
	6	2	Sep. 04	TX 6-116-252

CIG Media Group, L.P.				
Publication Name	Vol.	No.	Date of Pub.	Copyright #
	6	3	Nov. 04	TX 6-116-361
	6	S1	Dec. 04	TX 6-116-251
	6	S2	Dec. 04	TX 6-116-363
Clinical Lymphoma	1	1	Jun. 00	TX 5-338-293
	1	2	Sep. 00	TX 5-320-639
	1	3	Dec. 00	TX 5-318-992
	1	4	Mar. 01	TX 5-311-165
	1	S1	Nov. 00	TX 5-318-992
	2	1	Jun. 01	TX 5-416-623
	2	2	Sep. 01	TX 5-536-310
	2	3	Dec. 01	TX 5-519-349
	2	4	Mar. 02	TX 5-577-640
	2	S1	Mar. 02	TX 5-577-640
	3	1	Jun. 02	TX 5-704-639
	3	2	Sep. 02	TX 5-694-940
	3	3	Dec. 02	TX 5-729-347
	3	S1	Dec. 02	TX 5-729-347
	4	1	Jun. 03	TX 5-767-375
	4	1	Jun. 03	TX 5-867-778
	4	S1	Aug. 03	TX 5-859-027
	4	2	Sep. 03	TX 5-860-783
	4	3	Dec. 03	TX 5-967-065
	4	4	Mar. 04	TX 6-116-253
	5	S1	Oct. 04	TX 6-116-347
	5	1	Jun. 04	TX 6-116-360
	5	2	Sep. 04	TX 6-116-351
	5	3	Dec. 04	TX 6-116-254
5	4	Mar. 05	TX 6-156-644	
Clinical Prostate Cancer	1	1	Jun. 02	TX 5-690-453
	1	2	Sep. 02	TX 5-708-671
	1	3	Dec. 02	TX 5-712-263
	1	4	Mar. 03	TX 5-712-262
	2	2	Sep. 03	TX 5-855-604
	2	3	Dec. 03	TX 5-881-632
	2	4	Mar. 04	TX 5-972-248
	3	1	Jun. 04	TX 6-035-994
	3	2	Sep. 04	TX 6-100-925
	3	3	Dec. 04	TX 6-108-611
Supportive Cancer Therapy	1	1	Oct. 03	TX 5-834-402
	1	2	Jan. 04	TX 5-967-129
	1	3	Apr. 04	TX 6-116-362
	1	4	Jul. 04	TX 6-116-356

<b>CIG Media Group, L.P.</b>				
<b>Publication Name</b>	<b>Vol.</b>	<b>No.</b>	<b>Date of Pub.</b>	<b>Copyright #</b>
	2	1	Oct. 04	TX 6-116-250



CURE Media Group, L.P.				
Publication Name	Vol.	No.	Date of Pub.	Copyright #
C.U.R.E. Magazine <sup>1</sup>	1	1	Spring 02	
	1	2	Summer 02	
	1	3	Fall 02	
	1	4	Winter 02	
	2	1	Spring 03	
	2	2	Summer 03	
	2	3	Fall 03	
	2	4	Winter 03	
	3	1	Spring 04	
	3	2	Summer 04	
	3	3	Fall 04	
	3	4	Winter 04	
	4	1	Spring 05	
	4	2	Summer 05	

<sup>1</sup> All copyrights are pending applications.